{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:45:38Z","timestamp":1794012338659,"version":"4.8.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2021-12373603"],"award-info":[{"award-number":["RF-2021-12373603"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["52020-7"],"award-info":[{"award-number":["52020-7"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["E83C22004670001"],"award-info":[{"award-number":["E83C22004670001"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.biopha.2024.117153","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T19:06:26Z","timestamp":1721243186000},"page":"117153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Multiple antimicrobial and immune-modulating activities of cysteamine in infectious diseases"],"prefix":"10.1016","volume":"178","author":[{"given":"Tonino","family":"Alonzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Sali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Delogu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria Rachela","family":"Villella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Raia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Nicastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Piacentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Goletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.117153_bib1","unstructured":"WHO, The top 10 causes of death, (n.d.). \u3008https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death\u3009 (accessed April 24, 2024)."},{"key":"10.1016\/j.biopha.2024.117153_bib2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1055\/a-2095-0826","article-title":"Repurposing drugs: an empowering approach to drug discovery and development","volume":"73","author":"Kumar","year":"2023","journal-title":"Drug Res (Stuttg. )"},{"key":"10.1016\/j.biopha.2024.117153_bib3","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.3390\/molecules27092723","article-title":"Drug repurposing for COVID-19: a review and a novel strategy to identify new targets and potential drug candidates","volume":"27","author":"Rodrigues","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2024.117153_bib4","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMe2034982","article-title":"Baricitinib therapy in Covid-19 pneumonia - an unmet need fulfilled","volume":"384","author":"Goletti","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2024.117153_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cells11010052","article-title":"Cysteamine with in vitro antiviral activity and immunomodulatory effects has the potential to be a repurposing drug candidate for COVID-19 therapy","volume":"11","author":"Alonzi","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2024.117153_bib6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jpha.2020.03.007","article-title":"Challenges for cysteamine stabilization, quantification, and biological effects improvement","volume":"10","author":"Atallah","year":"2020","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.biopha.2024.117153_bib7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/10715762.2019.1612059","article-title":"Oxidative stress in biological systems and its relation with pathophysiological functions: the effect of physical activity on cellular redox homeostasis","volume":"53","author":"Kruk","year":"2019","journal-title":"Free Radic. Res"},{"key":"10.1016\/j.biopha.2024.117153_bib8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.molmed.2021.04.004","article-title":"Molecular mechanisms and treatment options of nephropathic cystinosis","volume":"27","author":"Jamalpoor","year":"2021","journal-title":"Trends Mol. Med"},{"key":"10.1016\/j.biopha.2024.117153_bib9","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/cells11030326","article-title":"Defective cystinosin, aberrant autophagy-endolysosome pathways, and storage disease: towards assembling the puzzle","volume":"11","author":"Rega","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2024.117153_bib10","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1080\/03007995.2017.1354288","article-title":"A systematic literature review of cysteamine bitartrate in the treatment of nephropathic cystinosis","volume":"33","author":"Medic","year":"2017","journal-title":"Curr. Med Res Opin."},{"key":"10.1016\/j.biopha.2024.117153_bib11","unstructured":"ClinicalTrials, Cysteamine | Card Results | ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/search?intr=cysteamine\u3009 (accessed April 24, 2024)."},{"key":"10.1016\/j.biopha.2024.117153_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15961","article-title":"Is cysteamine use effective in the treatment of melasma? A systematic review and meta-analysis","volume":"35","author":"Dos Santos-Neto","year":"2022","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.biopha.2024.117153_bib13","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.3389\/fneur.2019.01315","article-title":"Therapeutic applications of cysteamine and cystamine in neurodegenerative and neuropsychiatric diseases","volume":"10","author":"Paul","year":"2019","journal-title":"Front Neurol."},{"key":"10.1016\/j.biopha.2024.117153_bib14","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/cdd.2016.22","article-title":"A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR","volume":"23","author":"Tosco","year":"2016","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.biopha.2024.117153_bib15","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.lfs.2013.01.027","article-title":"Cystamine ameliorates ventricular hypertrophy associated with modulation of IL-6-mediated signaling in lupus-prone mice","volume":"92","author":"Tzang","year":"2013","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2024.117153_bib16","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/all.14332","article-title":"Cysteamine prevents asthma development and reduces airway hyperresponsiveness in experimental asthma","volume":"75","author":"Bolcas","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.biopha.2024.117153_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/2632010X231218075","article-title":"The global impact of COVID-19: historical development, molecular characterization, drug discovery and future directions","volume":"16","author":"Dofuor","year":"2023","journal-title":"Clin. Pathol."},{"key":"10.1016\/j.biopha.2024.117153_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1244556","article-title":"Initial immune response after exposure to Mycobacterium tuberculosis or to SARS-COV-2: similarities and differences","volume":"14","author":"Aiello","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2024.117153_bib19","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s40265-020-01421-w","article-title":"Immune therapy, or antiviral therapy, or both for COVID-19: a systematic review","volume":"80","author":"Cantini","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2024.117153_bib20","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1158\/2326-6066.CIR-21-0675","article-title":"Immune-guided therapy of COVID-19","volume":"10","author":"Ferraccioli","year":"2022","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.biopha.2024.117153_bib21","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41579-022-00713-0","article-title":"SARS-CoV-2 pathogenesis","volume":"20","author":"Lamers","year":"2022","journal-title":"Nat. Rev. Microbiol"},{"key":"10.1016\/j.biopha.2024.117153_bib22","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3390\/v15020553","article-title":"Hyperinflammatory response in COVID-19: a systematic review","volume":"15","author":"Silva","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2024.117153_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.708848","article-title":"Severe acute respiratory syndrome coronavirus-2 infection and autoimmunity 1 year later: the era of vaccines","volume":"12","author":"Picchianti Diamanti","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2024.117153_bib24","article-title":"Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies","author":"Aiello","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.biopha.2024.117153_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2022.10.035","article-title":"Booster dose of SARS-CoV-2 mRNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: a prospective multicenter longitudinal study","author":"Farroni","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.biopha.2024.117153_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.846753","article-title":"Kinetics of the B- and T-Cell immune responses after 6 months from SARS-CoV-2 mRNA vaccination in patients with rheumatoid arthritis","volume":"13","author":"Farroni","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2024.117153_bib27","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3390\/vaccines11111684","article-title":"Older age, a high titre of neutralising antibodies and therapy with conventional DMARDs are associated with protection from breakthrough infection in rheumatoid arthritis patients after the booster dose of anti-SARS-CoV-2 vaccine","volume":"11","author":"Picchianti-Diamanti","year":"2023","journal-title":"Vaccin. (Basel)"},{"key":"10.1016\/j.biopha.2024.117153_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1146704","article-title":"Impact of aging on immunity in the context of COVID-19, HIV, and tuberculosis","volume":"14","author":"Grifoni","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2024.117153_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk1599","article-title":"SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency","volume":"16","author":"Li","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2024.117153_bib30","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000013108","article-title":"INMI COVID-19 vaccine study group, humoral- and T-cell-specific immune responses to SARS-CoV-2 mRNA vaccination in patients with MS using different disease-modifying therapies","volume":"98","author":"Tortorella","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2024.117153_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.881988","article-title":"Humoral and cellular response to spike of delta SARS-CoV-2 variant in vaccinated patients with multiple sclerosis","volume":"13","author":"Petrone","year":"2022","journal-title":"Front Neurol."},{"key":"10.1016\/j.biopha.2024.117153_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2022.04.027","article-title":"Humoral and cellular responses to spike of \u03b4 SARS-CoV-2 variant in vaccinated patients with Immune Mediated Inflammatory Diseases","author":"Petrone","year":"2022","journal-title":"Int J. Infect. Dis."},{"key":"10.1016\/j.biopha.2024.117153_bib33","article-title":"B-cell-depleted patients with persistent SARS-CoV-2 infection: combination therapy or monotherapy? A real-world experience","volume":"11","author":"D\u2019Abramo","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.biopha.2024.117153_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1290614","article-title":"Combined antiviral therapy as effective and feasible option in allogenic hematopoietic stem cell transplantation during SARS-COV-2 infection: a case report","volume":"14","author":"Vita","year":"2024","journal-title":"Front Oncol."},{"key":"10.1016\/j.biopha.2024.117153_bib35","doi-asserted-by":"crossref","first-page":"8525","DOI":"10.3390\/ijms24108525","article-title":"Dynamic evolution of humoral and T-Cell specific immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis followed until the booster dose","volume":"24","author":"Ruggieri","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.117153_bib36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijid.2023.09.021","article-title":"Antiviral combination therapies for persistent COVID-19 in immunocompromised patients","volume":"137","author":"Focosi","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.biopha.2024.117153_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(23)00815-0","article-title":"Persistent SARS-CoV-2 infection: significance and implications","author":"Machkovech","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.biopha.2024.117153_bib38","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbrc.2023.08.021","article-title":"Cysteamine-mediated blockade of the glycine cleavage system modulates epithelial cell inflammatory and innate immune responses to viral infection","volume":"677","author":"Fraser-Pitt","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2024.117153_bib39","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8856018","article-title":"In vitro models for studying entry, tissue tropism, and therapeutic approaches of highly pathogenic coronaviruses","volume":"2021","author":"Najafi Fard","year":"2021","journal-title":"BioMed. Res. Int."},{"key":"10.1016\/j.biopha.2024.117153_bib40","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1750-1172-6-86","article-title":"Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients","volume":"6","author":"Bouazza","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.biopha.2024.117153_bib41","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ymgme.2022.08.009","article-title":"In vitro activity of cysteamine against SARS-CoV-2 variants","volume":"137","author":"Thoene","year":"2022","journal-title":"Mol. Genet Metab."},{"key":"10.1016\/j.biopha.2024.117153_bib42","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41420-022-01080-8","article-title":"Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants","volume":"8","author":"Alonzi","year":"2022","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.biopha.2024.117153_bib43","doi-asserted-by":"crossref","first-page":"L372","DOI":"10.1152\/ajplung.00136.2022","article-title":"Exploring antiviral and anti-inflammatory effects of thiol drugs in COVID-19","volume":"323","author":"Khanna","year":"2022","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.biopha.2024.117153_bib44","doi-asserted-by":"crossref","first-page":"286.e7","DOI":"10.1016\/j.cmi.2020.09.051","article-title":"A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients","volume":"27","author":"Petrone","year":"2021","journal-title":"Clin. Microbiol Infect."},{"key":"10.1016\/j.biopha.2024.117153_bib45","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.ebiom.2015.08.018","article-title":"Cysteamine as a future intervention in cystic fibrosis against current and emerging pathogens: a patient-based ex vivo study confirming its antimicrobial and mucoactive potential in sputum","volume":"2","author":"Devereux","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.biopha.2024.117153_bib46","unstructured":"WHO, Global Tuberculosis Report 2023, (2023). \u3008https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2023\u3009 (accessed March 22, 2024)."},{"key":"10.1016\/j.biopha.2024.117153_bib47","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2024.117153_bib48","doi-asserted-by":"crossref","first-page":"284","DOI":"10.5588\/ijtld.22.0685","article-title":"Epidemiology, pathogenesis, clinical presentation and management of TB in patients with HIV and diabetes","volume":"27","author":"Goletti","year":"2023","journal-title":"Int. J. Tube Lung Dis."},{"key":"10.1016\/j.biopha.2024.117153_bib49","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/14740338.2019.1612872","article-title":"Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice","volume":"18","author":"Cantini","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.biopha.2024.117153_bib50","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.3389\/fimmu.2019.03042","article-title":"Inhibition of transglutaminase 2 as a potential host-directed therapy against mycobacterium tuberculosis","volume":"10","author":"Palucci","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2024.117153_bib51","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41419-018-0640-8","article-title":"Clinical isolates of the modern Mycobacterium tuberculosis lineage 4 evade host defense in human macrophages through eluding IL-1\u03b2-induced autophagy","volume":"9","author":"Romagnoli","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2024.117153_bib52","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/joim.12714","article-title":"Transglutaminase type 2 plays a key role in the pathogenesis of Mycobacterium tuberculosis infection","volume":"283","author":"Palucci","year":"2018","journal-title":"J. Intern Med"},{"key":"10.1016\/j.biopha.2024.117153_bib53","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.4049\/jimmunol.2001122","article-title":"Transglutaminase 2 Regulates Innate Immunity by Modulating the STING\/TBK1\/IRF3 Axis","volume":"206","author":"Occhigrossi","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2024.117153_bib54","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000490478","article-title":"Host directed therapies for tuberculosis: futures strategies for an ancient disease","volume":"63","author":"Palucci","year":"2018","journal-title":"Chemotherapy"},{"key":"10.1016\/j.biopha.2024.117153_bib55","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.3390\/jcm9082541","article-title":"General overview of nontuberculous mycobacteria opportunistic pathogens: mycobacterium avium and mycobacterium abscessus","volume":"9","author":"To","year":"2020","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.biopha.2024.117153_bib56","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1128\/CMR.00035-14","article-title":"Microbiological features and clinical relevance of new species of the genus Mycobacterium","volume":"27","author":"Tortoli","year":"2014","journal-title":"Clin. Microbiol Rev."},{"key":"10.1016\/j.biopha.2024.117153_bib57","doi-asserted-by":"crossref","DOI":"10.1007\/s15010-024-02183-3","article-title":"Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine","author":"Calcagno","year":"2024","journal-title":"Infection"},{"key":"10.1016\/j.biopha.2024.117153_bib58","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1080\/17476348.2021.1987891","article-title":"Nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex - disease burden, unmet needs, and advances in treatment developments","volume":"15","author":"van Ingen","year":"2021","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.biopha.2024.117153_bib59","article-title":"Alternative therapies against Mycobacterium abscessus infections","author":"Palucci","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.biopha.2024.117153_bib60","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3390\/ijms24021203","article-title":"Cysteamine\/cystamine exert anti-mycobacterium abscessus activity alone or in combination with amikacin","volume":"24","author":"Palucci","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.117153_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106148","article-title":"Redox homeostasis as a target for new antimycobacterial agents","volume":"56","author":"Fraternale","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.biopha.2024.117153_bib62","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1164\/rccm.200408-1044SO","article-title":"Pathogen-host interactions in Pseudomonas aeruginosa pneumonia","volume":"171","author":"Sadikot","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.biopha.2024.117153_bib63","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","article-title":"Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies","volume":"37","author":"Pang","year":"2019","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.biopha.2024.117153_bib64","doi-asserted-by":"crossref","first-page":"11895","DOI":"10.3390\/ijms241511895","article-title":"Transcriptional regulators controlling virulence in Pseudomonas aeruginosa","volume":"24","author":"S\u00e1nchez-Jim\u00e9nez","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.117153_bib65","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.3390\/antibiotics12111590","article-title":"Evaluation of antibiotic resistance mechanisms in gram-negative bacteria","volume":"12","author":"Gauba","year":"2023","journal-title":"Antibiot. (Basel)"},{"key":"10.1016\/j.biopha.2024.117153_bib66","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3389\/fcimb.2020.00266","article-title":"Impact of coexistence phenotype between Staphylococcus aureus and Pseudomonas aeruginosa isolates on clinical outcomes among cystic fibrosis patients","volume":"10","author":"Briaud","year":"2020","journal-title":"Front Cell Infect. Microbiol."},{"key":"10.1016\/j.biopha.2024.117153_bib67","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.3390\/ijms20143423","article-title":"Biofilms: the microbial \u201cprotective clothing\u201d in extreme environments","volume":"20","author":"Yin","year":"2019","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.117153_bib68","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13023-014-0189-2","article-title":"Cysteamine (Lynovex\u00ae), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis","volume":"9","author":"Charrier","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.biopha.2024.117153_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186169","article-title":"Cysteamine-mediated clearance of antibiotic-resistant pathogens in human cystic fibrosis macrophages","volume":"12","author":"Shrestha","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2024.117153_bib70","article-title":"Altering the interfacial rheology of Pseudomonas aeruginosa and Staphylococcus aureus with N-acetyl cysteine and cysteamine","volume":"13","author":"Balmuri","year":"2023","journal-title":"Front Cell Infect. Microbiol."},{"key":"10.1016\/j.biopha.2024.117153_bib71","doi-asserted-by":"crossref","first-page":"e00947","DOI":"10.1128\/IAI.00947-17","article-title":"Cysteamine, an endogenous aminothiol, and cystamine, the disulfide product of oxidation, increase Pseudomonas aeruginosa sensitivity to reactive oxygen and nitrogen species and potentiate therapeutic antibiotics against bacterial infection","volume":"86","author":"Fraser-Pitt","year":"2018","journal-title":"Infect. Immun."},{"key":"10.1016\/j.biopha.2024.117153_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.718213","article-title":"Cysteamine inhibits glycine utilisation and disrupts virulence in Pseudomonas aeruginosa","volume":"11","author":"Fraser-Pitt","year":"2021","journal-title":"Front Cell Infect. Microbiol"},{"key":"10.1016\/j.biopha.2024.117153_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.476","article-title":"Cysteamine re-establishes the clearance of Pseudomonas aeruginosa by macrophages bearing the cystic fibrosis-relevant F508del-CFTR mutation","volume":"8","author":"Ferrari","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2024.117153_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184793","article-title":"Dendrimer-based selective autophagy-induction rescues \u0394F508-CFTR and inhibits Pseudomonas aeruginosa infection in cystic fibrosis","volume":"12","author":"Brockman","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2024.117153_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1093212","article-title":"The STING\/TBK1\/IRF3\/IFN type I pathway is defective in cystic fibrosis","volume":"14","author":"Occhigrossi","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2024.117153_bib76","doi-asserted-by":"crossref","first-page":"9607","DOI":"10.1039\/D1FO01352A","article-title":"Research progress of epigallocatechin-3-gallate (EGCG) on anti-pathogenic microbes and immune regulation activities","volume":"12","author":"Zhao","year":"2021","journal-title":"Food Funct."},{"key":"10.1016\/j.biopha.2024.117153_bib77","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.4161\/15548627.2014.973737","article-title":"Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation","volume":"10","author":"Stefano","year":"2014","journal-title":"Autophagy"},{"key":"10.1016\/j.biopha.2024.117153_bib78","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1172\/JCI117223","article-title":"Cystamine potently suppresses in vitro HIV replication in acutely and chronically infected human cells","volume":"93","author":"Bergamini","year":"1994","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2024.117153_bib79","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/infdis\/174.1.214","article-title":"In vitro inhibition of the replication of human immunodeficiency virus type 1 by beta-mercaptoethylamine (cysteamine)","volume":"174","author":"Bergamini","year":"1996","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.biopha.2024.117153_bib80","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/aid.1995.11.451","article-title":"Cystamine inhibits HIV type 1 replication in cells of monocyte\/macrophage and T cell lineages","volume":"11","author":"Ho","year":"1995","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.biopha.2024.117153_bib81","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1182\/blood.V88.3.928.928","article-title":"Cystamine inhibits human immunodeficiency virus-1 replication in cord blood-derived mononuclear phagocytes and lymphocytes","volume":"88","author":"Ho","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2024.117153_bib82","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1086\/515276","volume":"177","author":"Goletti","year":"1998","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.biopha.2024.117153_bib83","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.bbrc.2017.05.172","article-title":"Metabolic pathway catalyzed by Vanin-1 pantetheinase plays a suppressive role in influenza virus replication in human alveolar epithelial A549 cells","volume":"489","author":"Yamashita","year":"2017","journal-title":"Biochem. Biophys. Res Commun."},{"key":"10.1016\/j.biopha.2024.117153_bib84","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.antiviral.2007.11.004","article-title":"Inhibition of murine AIDS by pro-glutathione (GSH) molecules","volume":"77","author":"Fraternale","year":"2008","journal-title":"Antivir. Res."},{"key":"10.1016\/j.biopha.2024.117153_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166918","article-title":"A synthetic thiol molecule releasing N-acetyl-l-cysteine and cysteamine drives early up-regulation of immunoproteasome subunits in the lymph nodes of mice infected with LP-BM5 leukemia retrovirus","volume":"1870","author":"Crinelli","year":"2024","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.biopha.2024.117153_bib86","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1038\/s41598-022-10609-x","article-title":"Clearance of mixed biofilms of Streptococcus pneumoniae and methicillin-susceptible\/resistant Staphylococcus aureus by antioxidants N-acetyl-L-cysteine and cysteamine","volume":"12","author":"Sempere","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.117153_bib87","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01992-16","article-title":"N-acetyl-l-cysteine and cysteamine as new strategies against mixed biofilms of nonencapsulated Streptococcus pneumoniae and nontypeable haemophilus influenzae","volume":"61","author":"Domenech","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2024.117153_bib88","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.joen.2016.01.020","article-title":"Cysteamine enhances biofilm eradication efficacy of calcium hydroxide","volume":"42","author":"Guo","year":"2016","journal-title":"J. Endod."},{"key":"10.1016\/j.biopha.2024.117153_bib89","first-page":"448","article-title":"Cysteamine improves the bactericidal efficacy of intra-canal medicaments against Enterococcus faecalis","volume":"91","author":"Pandey","year":"2018","journal-title":"Clujul Med."},{"key":"10.1016\/j.biopha.2024.117153_bib90","doi-asserted-by":"crossref","first-page":"6200","DOI":"10.1128\/AAC.01198-16","article-title":"Activity of cysteamine against the cystic fibrosis pathogen burkholderia cepacia complex","volume":"60","author":"Fraser-Pitt","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2024.117153_bib91","unstructured":"WHO, World malaria report 2022, (n.d.). \u3008https:\/\/www.who.int\/publications-detail-redirect\/9789240064898\u3009 (accessed April 24, 2024)."},{"key":"10.1016\/j.biopha.2024.117153_bib92","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1084\/jem.20061252","article-title":"Complex genetic control of susceptibility to malaria: positional cloning of the Char9 locus","volume":"204","author":"Min-Oo","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2024.117153_bib93","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.exppara.2010.02.009","article-title":"Cysteamine, the natural metabolite of pantetheinase, shows specific activity against Plasmodium","volume":"125","author":"Min-Oo","year":"2010","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.biopha.2024.117153_bib94","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1128\/AAC.01719-09","article-title":"Cysteamine, the molecule used to treat cystinosis, potentiates the antimalarial efficacy of artemisinin","volume":"54","author":"Min-Oo","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2024.117153_bib95","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12936-016-1317-3","article-title":"Cysteamine broadly improves the anti-plasmodial activity of artemisinins against murine blood stage and cerebral malaria","volume":"15","author":"Moradin","year":"2016","journal-title":"Malar. J."},{"key":"10.1016\/j.biopha.2024.117153_bib96","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1016\/j.ajpath.2015.07.011","article-title":"Serum pantetheinase\/vanin levels regulate erythrocyte homeostasis and severity of malaria","volume":"185","author":"Rommelaere","year":"2015","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2024.117153_bib97","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.molbiopara.2004.03.011","article-title":"Dependence of Giardia lamblia encystation on novel transglutaminase activity","volume":"136","author":"Davids","year":"2004","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.biopha.2024.117153_bib98","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1128\/AAC.39.9.1913","article-title":"Transglutaminase-catalyzed reaction is important for molting of Onchocerca volvulus third-stage larvae","volume":"39","author":"Lustigman","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2024.117153_bib99","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.exppara.2006.02.021","article-title":"Leishmania species: evidence for transglutaminase activity and its role in parasite proliferation","volume":"114","author":"Brobey","year":"2006","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.biopha.2024.117153_bib100","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1128\/AAC.35.11.2219","article-title":"Brugia malayi and Acanthocheilonema viteae: antifilarial activity of transglutaminase inhibitors in vitro","volume":"35","author":"Rao","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2024.117153_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.1035765","article-title":"Pathology and molecular mechanisms of Schistosoma japonicum-associated liver fibrosis","volume":"12","author":"Liu","year":"2022","journal-title":"Front Cell Infect. Microbiol."},{"key":"10.1016\/j.biopha.2024.117153_bib102","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/753483","article-title":"Involvement of IL-13 and tissue transglutaminase in liver granuloma and fibrosis after schistosoma japonicum infection","volume":"2014","author":"Tang","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.biopha.2024.117153_bib103","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1186\/s13023-021-01991-2","article-title":"A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis","volume":"16","author":"van Stein","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.biopha.2024.117153_bib104","unstructured":"Thiogenesis Therapeutics, Lead Compound TTI-0102, (n.d.). \u3008https:\/\/www.thiogenesis.com\/science\u3009 (accessed April 24, 2024)."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224010370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224010370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:21:29Z","timestamp":1778541689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224010370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":104,"alternative-id":["S0753332224010370"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117153","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple antimicrobial and immune-modulating activities of cysteamine in infectious diseases","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117153","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117153"}}